The Digital Revolution: The Genesis of Patient-Driven Healthcare

Digital technology is reshaping the very contours of modern healthcare with the potential to sustainably transform the industry as we know it. The broad scope of digital health, as defined by the FDA, includes categories such as health information technology, telehealth, wearable devices, telemedicine and personalised medicine.  By converging digital health and genomic technologies with […]

Read More →

Problems with Today’s Cancer Drugs

Having the notorious status of being the ‘deadliest disease in the developed world’, cancer unscrupulously affects thousands of people across the globe each year. In 2021, it is estimated that cancer will be responsible for one in six deaths, making it the second most common cause of death globally (WHO, 2020). In Australia alone, it […]

Read More →

GBS, Inc. receives approval to commence validation clinical study for rapid SARS-CoV-2 diagnostic test

NEW YORK APRIL 15, 2021 — GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a validation study to test clinical samples from […]

Read More →

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests

New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generation saliva-based diagnostic tests. […]

Read More →

Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic

Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications. This article has been republished with permission from the Wyss Institute at Harvard University. Click here to view the original article. By Benjamin Boettner (BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard […]

Read More →